Oxford Instruments experienced a significant drop in its share price after releasing preliminary results for the year ended 31 March 2026, with the stock down 6.6% to trade at 2,882p. The scientific instruments maker reported a year-on-year contraction in both top-line revenue and core profitability, outcomes that disappointed investors who had pushed the shares close to their 52-week high in anticipation of the update.
On a reported basis, full-year revenue declined 4.6% to 423.2 million, while adjusted operating profit decreased 7.3% to 73.7 million. Adjusted earnings from continuing operations were 99.7p per share, down from 107.8p per share in the prior year.
Although these numbers slightly exceeded the analyst consensus that had been pared back over the course of the year - revenue of 423.2 million beat a 422.1 million estimate, and adjusted operating profit of 73.7 million topped the 68.1 million consensus - the consensus itself had been reduced multiple times during the year. That lowered bar limited the positive surprise on results day.
At the divisional level, Imaging & Analysis recorded a 3.0% drop in revenue. In contrast, the Advanced Technologies arm showed strength in order intake, with a 28% increase driven by demand for compound semiconductor applications. Management noted that the stronger order book in Advanced Technologies has not yet been converted into recognised revenue within the reported period.
Separately, the group completed the divestment of its NanoScience business in January 2026, receiving 42 million in net proceeds. That disposal removed a revenue-contributing unit from the group's reported figures for the year.
Market conditions provided little offset for the company-specific weakness. U.S. equity markets were mixed on the day of the announcement, and there was no notable UK macro catalyst to buoy sentiment in the technology and scientific instruments sector.
Investor positioning ahead of the results magnified the reaction. The stock had rallied substantially from its 52-week low of 1,682p and was trading close to its 52-week high of 3,318p as the company entered results day. With the share price already reflecting high expectations, the combination of profit compression, an earnings-per-share decline, and only a modest beat versus already-reduced forecasts set the stage for a pronounced sell-the-news response. The share price fell sharply from the prior session close of 3,086p, moving toward the session low of 2,822p.
Management did offer some shareholder-friendly measures: a proposed 6.3% increase in the full-year dividend to 23.6p per share and 62.2 million in completed share buybacks. While these actions provide some cash-return context for shareholders, they were insufficient to offset the deterioration in adjusted earnings per share in the view of the market.
In sum, the interplay of year-on-year profit decline, prior share-price appreciation, and only a marginal upside to lowered analyst expectations produced a swift negative market reaction on the results announcement.
Summary
Oxford Instruments reported lower revenue and adjusted operating profit for the year ended 31 March 2026, with adjusted earnings from continuing operations down to 99.7p per share. Although the group narrowly beat reduced analyst forecasts and announced higher dividend and completed buybacks, the results prompted a steep decline in the share price as investors sold into the news.
Key points
- Full-year revenue fell 4.6% to 423.2 million; adjusted operating profit declined 7.3% to 73.7 million.
- Advanced Technologies saw a 28% rise in order intake driven by compound semiconductor demand, but that order strength has not yet been recognised as revenue.
- Shareholder-friendly measures included a proposed 6.3% dividend increase to 23.6p and 62.2 million of completed buybacks, but these did not prevent the stock from falling sharply.
Risks and uncertainties
- Profitability risk - year-on-year compression in adjusted operating profit and earnings per share indicates pressure on core margins and profitability for the group, which affects investor sentiment in the technology and scientific instruments sectors.
- Revenue conversion risk - the Advanced Technologies segment's stronger order intake has not yet translated into recognised revenue, creating uncertainty about near-term top-line recovery.
- Valuation risk - with the share price having risen close to its 52-week high ahead of the results, the stock was vulnerable to a sell-the-news reaction if outcomes failed to substantially exceed already-reduced expectations.